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Abstract
Antibiotics have been recommended either as an extended treatment for several days
or as a single antibiotic prophylaxis dose since the development of dental implant
osseointegration technique in the 1970s. It is also performed as part of surgical protocol
during the peri-operative phase in the treatment of peri-implantitis. To date, there is a
lack of scientific evidence regarding the additive effect of antibiotics in the treatment of
dental implant. This has thus left the clinician with inconclusive recommendations,
leading to  increase  antibiotic  prescription.  With  this  increase,  the  development  of
antibiotic resistance is becoming a threat to modern healthcare that requires revisiting
of current indications and implementation of rational treatment strategies. Therefore,
more studies are needed to assess the benefit of antibiotic prescription and whether it
is safe to refrain from its use.
Keywords: Dental implant failure, dental implant surgery, antibiotic prophylaxis,
treatment of peri-implantitis, selection of antibiotic resistance
1. Introduction
Since the introduction of dental implants as treatment for missing teeth, systemically admin‐
istered antibiotics have been used to prevent and treat implant failure. In conjunction with
implant placement, antibiotics have been recommended either as extended treatment or short-
term prophylaxis during the peri-operative period. In the treatment of peri-implantitis, the
majority of surgical flap protocols described in the literature also include administration of
systemic antibiotics in the peri-operative phase.
Today, antibiotic resistance is the largest threat to modern healthcare where many treatment
options, including advanced surgical interventions, require access to effective antibiotics [1].
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Therefore, original or consensus-based recommendations, such as the use of antibiotics in
implant dentistry, are being reevaluated. Previous policies of prescribing antibiotics, until it
is proven safe to refrain from their use, are today considered an outdated option in otherwise
healthy patients. Currently, the potential risk of using antibiotics must be weighed against
possible benefits for individual patients when undergoing dental implant treatment.
A dental implant is a titanium device anchored and integrated into the jawbone. Osseointe‐
grated dental implants have been an established treatment modality for replacing missing
teeth since the beginning of the 1970s [2]. A substantial number of studies using long-term
follow-ups have shown successful results for patients with partially and completely edentu‐
lous jaws [3–8]. Survival rates of 90–100% of inserted implants have been reported in several
longitudinal studies during follow-ups of up to 20 years later [4, 9–14]. Despite the high success
rate of dental implants, failures do occur.
Biological implant failures may be categorized into early failures, that is, failure to achieve
osseointegration due to surgical trauma, infection, lack of primary stability [15], or late failures,
that is, failure to maintain the achieved osseointegration, due to occlusal overload, peri-
implantitis, or both [15]. Implant failure is an outcome that may require implant removal [15].
2. Prophylactic use of antibiotics during surgery
2.1. Peri-operative antibiotic treatment and extended prophylaxis
The empirically based tradition of using a peri-operative systemically administered prescrip‐
tion of antibiotics originates from the introduction of the treatment method by PI Brånemark
and collaborators [2] during the 1970s. The original implant placement protocol recommended
the use of antibiotic treatment during the initial phase of healing, for up to 10 days, to prevent
postoperative infection and early implant failure [16, 17]. A two-staged surgical protocol for
implant placement was initially introduced to further prevent infection [18]. The rationale for
prescribing the extended antibiotic prophylaxis was, at the time of introduction, based on
empiric medical/orthopedic considerations. Today, one has to remember that one of the key
factors in making the method successful was the addition of a tissue preserving surgical
technique. This technique minimized the risk of bacterial contamination during surgery, which
at the time included the extended use of systemic antibiotic treatment.
It has been shown that bacterial contamination during implant insertion may be one of the
major reasons for early implant failure [19]. Oral implant surgical procedures are often graded
as class II surgical procedures (clean-contaminated surgery) [20, 21]. Clean-contaminated
surgery has a local infection rate of 10–15% (Figure 1). However, the incidence of infection can
be reduced to 1% or less with proper surgical technique and the use of prophylactic antibiotics
[20, 21]. Conversely, prophylactic antibiotics can never make up for poor surgical technique
and hygienic measures. However, during the past decade, due to the emergence of bacterial
antibiotic resistance, the recommendation of extended prophylactic antibiotic treatment has
been challenged. Scientific evidence from various surgical fields including placement of dental
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implants shows no benefit of antibiotic prophylaxis beyond the day of surgery in uncompli‐
cated routine cases [22–25]. Therefore, this extended antibiotic treatment is now increasingly
being replaced by a single-dose antibiotic prophylaxis.
Figure 1. Surgical wound infection classification and the estimated percentage risk for postoperative infections [20, 21].
2.2. Short-term, single-dose antibiotic prophylaxis
There are several clinical studies [26–36] summarized in systematic reviews showing that the
use of prophylactic antibiotics during dental implant insertion reduces the risk of implant
failure [22, 37]. However, this finding has recently been questioned [38, 39]. For example, none
of the randomized controlled studies included in a recent meta-analysis [38] showed a
statistically significant beneficial effect of antibiotic prophylaxis on their own [27, 30, 31, 40,
41], although the beneficial effect could not be excluded in complex or compromised patients
[38, 42]. Therefore, this issue remains a controversial subject under constant revision, and
recommendations based on sound scientific evidence are still lacking. Despite this, the routine
use of antibiotics during implant placement continues to be common among the majority of
dentists in most countries [43–45]. These results today have thus left the clinician with
inconclusive recommendations. However, it should also be kept in mind that there are several
factors in addition to the use of prophylactic antibiotics during implant placement that can
affect implant success rates, such as implant systems, duration of surgery, the number of
implants placed, as well as surgical skills [29].
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3. The use of antibiotics for the treatment of peri-implant infection
When a dental implant is inserted into the oral cavity, it provides a new and physically different
surface for the colonization of microorganisms. The development of this new biofilm is a
process strongly resembling biofilm formation on natural teeth [46–51]. The colonization of
microorganisms on this new surface has been shown to start within hours after insertion, with
a microflora already resident in the oral cavity [52, 53].
Peri-implantitis was initially defined as “a site-specific infection with many features in
common with chronic adult periodontitis” [54] and/or as “an inflammatory, bacterial-driven
destruction of the implant supporting tissues” [55]. Both definitions imply that bacteria may
play a crucial role in the initiation and progression of peri-implantitis. With time varying from
months to years, the implant microflora has shown to become more complex if soft tissue
inflammation and pocket formation develop around a dental implant (i.e., clinical signs of peri-
implantitis) [56].
Studies have shown that when comparing clinically healthy peri-implant sites to sites with
peri-implantitis, a transition in microflora composition can be seen [57, 58]. A shift from
predominantly nonmotile, aerobic, and facultative anaerobic bacteria to a biofilm with a high
proportion of gram-negative, motile, anaerobic bacteria has occurred [59, 60]. Moreover,
residual teeth (not edentulous or partially edentulous) and clinical condition (periodontally
healthy teeth or persisting ongoing periodontitis with residual probing) have been shown to
influence the development of the subgingival microflora around dental implants [61, 62]. In
partially edentulous patients, the adjacent teeth play a role in the periodontal pathogen
colonization [63–65]. Accumulation of a microbial biofilm on the implant surface promotes an
inflammatory response in the peri-implant mucosa, resulting in peri-implant mucositis. This
is characterized as a reversible inflammation of the soft tissues, with reddening, swelling, and
bleeding on probing [66–68]. Persistence of inflammation may result in the loss of peri-implant
supporting tissues which is defined as peri-implantitis [42, 54, 55, 68]. Peri-implantitis appears
to be associated with a similar microflora as that found in chronic periodontitis such as
Porphyromonas gingivalis, Tannerella forsythia, and Aggregatibacter actinomycetemcomitans [69–
73]. However, compared with periodontitis, some bacteria, which are not part of the typical
periodontopathic microbiota, have been found in peri-implantitis lesions such as staphylo‐
cocci, enteric rods, and Candida [74, 75].
Peri-implantitis has become a prevalent, notable disease, affecting a substantial number of
patients [76]. However, a recent review indicates a wide variation in the incidence and
prevalence of peri-implantitis [76]. This variation is most likely due to patient/case selection,
diagnostic criteria used, and varying time of follow-up. Tomasi and Derks [76] in a recent
review stated that the prevalence of peri-implantitis varies between 8.9 and 47% of implants.
In 2012, the EAO Consensus Conference stated that peri-implantitis occurred in one of five
patients within 5 years following implant placement [77].
Treatment of peri-implantitis is directed towards removing the biofilm, resolving the inflam‐
mation, and arresting the progression of bone loss. Various protocols have been suggested as
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a method for achieving this [78]. The primary objective was to alter the microbiota and induce
the host immune system to eliminate putative pathogens [79]. Mechanical debridement and
disinfection of implant surfaces are directed to remove the oral biofilm and perio-pathogenic
microbes to a certain extent [80]. Indeed, the surface characteristics and the screw-shaped
configuration of most current implants may influence the resolution of the inflammation in
the surrounding tissues [79]. Conventional mechanical therapies currently used in the
treatment of periodontitis may therefore be difficult to apply around dental implants [79].
It is therefore difficult to treat peri-implantitis, and the outcome may not be predictable [68].
To date, there is no standard protocol for the treatment of peri-implantitis. A nonsurgical
treatment alone appears to be insufficient in resolving peri-implantitis lesions and is less
successful in arresting disease recurrence in long-term follow-up [68, 81].
Surgical treatment of peri-implantitis allows better access for the removal of granulation tissue
and decontamination of exposed implant surfaces [68]. Since the etiology of peri-implantitis
is similar to periodontitis, the anti-infective protocol used with periodontitis has been adopted
in the treatment of peri-implantitis. In the treatment of aggressive periodontitis, the use of
adjunctive systematic antibiotics (amoxicillin and metronidazole) has shown an additional
effect. The combination of amoxicillin and metronidazole has the potential to decrease a wide
range of oral bacteria usually associated with peri-implantitis [82]. Studies including surgical
treatment of peri-implantitis in combination with the use of amoxicillin (500 mg) and metro‐
nidazole (400 mg) for 7 days have shown a 58% success rate for implants with machined
surfaces [83, 84]. However, in a majority of prospective clinical studies, the parallel effect of
several procedures has been evaluated simultaneously [83–86]. These procedures include
access flap procedures as well as reconstructive/regenerative procedures. Regardless of
surgical technique, adjunctive treatment of systemically administered antibiotics has been
used. Therefore, the knowledge of a single specific intervention, such as the adjunctive use of
systematic antibiotic, is still limited [87, 88].
In a recent RCT including 100 patients, surgical treatment of peri-implantitis was performed
with or without adjunctive systemic antibiotics [89]. The results of this study showed that the
use of adjunctive systematic antibiotics combined with surgical treatment of peri-implantitis
had a limited significant effect on implant success. However, there is an increase in the
probability of treatment success of implants with a modified surface, but not at implants with
a nonmodified/smooth surface [89]. The overall implant treatment success after a 1-year
follow-up was 45% [89]. As presented in the scientific literature to date and concluded in a
consensus from 2012 at the 8th European Workshop in Periodontology [88], the adjunctive use
of systemic antibiotics on treatment outcome is still limited in the treatment of peri-implantitis.
4. Antibiotic delivery route with dental implants
The use of oral antibiotics is one of the most common approaches in treating bacterial infec‐
tions. Antibiotics can be delivered either systemically or by direct placement into the pocket
around the dental implant. Each method of delivery has specific advantages and disadvan‐
tages. However, based on clinical and microbiological evidence, the type of microorganisms
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responsible for the infection is treated on a presumptive basis, founded on probabilistic
reasoning [90]. A wide range of antibiotic compounds and dose regiments is presented in the
literature. Ideally, antibiotic treatment duration should include the shortest efficient cycle for
preventing both clinical and microbiological relapse [91]. However, this short cycle should
ideally have certain characteristics such as rapid onset of action; bactericidal activity; lack of
propensity to promote resistant mutants; ease of invasion into tissues; activity against
nondividing bacteria; unaffected by adverse infection conditions (low pH, presence of pus,
etc.); administration at an optimal dose; and an optimal and convenient dosing regimen [92].
4.1. Local use of antibiotics
Local delivery facilitates the application of antimicrobial agents at levels that cannot be reached
by the systemic route. However, these levels need to be maintained at a high local concentration
for a long period of time, and the agents should reach the entire affected area, that is, the base
of the pocket, in order to be efficient. This type of delivery varies from simple pocket irrigation
and specifically placed drug-containing ointments and gels, to sophisticated tools for sustained
release of antibacterial agents. However, it is unlikely that mouth rinse or supragingival
irrigation could predictably deliver an agent to the deeper parts of the defect because the
crevicular fluid rapidly washes out agents from the pockets [93, 94]. Nevertheless, there is a
low incidence of side effects with locally applied antibiotics. The use of local antibiotics as an
adjunctive in the treatment of peri-implantitis has shown no or limited effect on the reduction
of periodontal pocket depth and gain in clinical attachment level [95, 96]. This lack of significant
clinical additive effects of local antibiotic supplement is may be due to inadequate exposure
of the subgingival bacteria to the compound.
4.2. Systematic use of antibiotics
Systemic use of antibiotics is commonly recommended when the targeted bacteria are more
widely spread, which is beyond the site of initial infection. The periodontal bacteria may be
found throughout the whole oral cavity including on non-dental sites such as the dorsum of
the tongue or tonsillary crypts [97–103]. However, this colonization of perio-pathogens at
various oral ecological niches is not to be regarded as a systemic infection and does not call
for systemic antimicrobial treatment. The drawback of systematic administration is the high
rate of drug dissemination throughout the body, where only a small portion reaching the
subgingival microflora in the periodontal pocket [104]. Moreover, adverse drug reactions are
of greater concern. Systemic antibiotics should never be applied as compensation for inade‐
quate oral hygiene.
5. Antibiotic compounds commonly used in implant dentistry
Antibiotic compounds can be classified in a number of different ways: (a) by their origin
(natural, semisynthetic or synthetic drugs); (b) by their mode of antibacterial activity as
bacteriostatic (growth inhibiting), or bacteriocidal (drugs kill the bacteria); (c) by antibacterial
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spectrum (broad-spectrum or narrow-spectrum), or (d) by their cellular mechanism of action,
for example:
i. Cell wall inhibitors, such as the beta-lactam antibiotics penicillin and carbapenem
ii. Inhibitors of nucleic acid synthesis, such as quinolones and metronidazole, which
inhibit DNA synthesis, and rifampincin which inhibits RNA synthesis
iii. Protein synthesis inhibitors, such as tetracycline and clindamycin
iv. Anti-metabolites, such as the sulfa drugs
v. Antibiotics that can damage the cell membrane, such as polymyxin B and daptomycin
Amoxicillin Clindamycin Metronidazole Penicillin-V
Spectrum Streptococcus
Peptostreptococcus
Actinomyces
Fusobacterium
Capnocytophaga
Streptococcus
Staphylococcus
Bacteroids
Fusobacterium
Prevotella
Anaerobic cocci
Peptostreptococcus
Clostridium
Bacteroids
Prophyromonas
Prevotella
Fusobacterium
Capnocytophaga
Streptococcus
Peptostreptococcus
Actinomyces
Fusobacterium
Capnocytophaga
Effect Time dependent Concentration
dependent
Concentration
dependent
Time dependent
Pharmacokinetic
Absorption (p.o.)
T½
Solubility
Excretion
90%
~1 h
Water
Urine
90%
~2, 5 h
Fat
Gall bladder, feces, urine
>95%
~8 h
Fat
Urine and
gall bladder
50%
~30 min
Water
Urine
Common side
effect
Vomiting, diarrhea,
nausea, exanthema
(5%)
Vomiting, diarrhea,
nausea
(8%)
Gastrointestinal
upset, metallic
taste
(5–10%)
Diarrhea, nausea
(5%)
Ecological effect
Oral
Gastrointestinal
++
++
+++
+++
++
+
++
+
P.O. peroral; T½ half time; + mild/no effect; ++ moderate effect; +++ severe effect.
Table 1. Summary of characteristics of the most common antibiotic compounds used in implant dentistry.
Although there are numerous antimicrobial agents available, only a limited number of
systemic antibiotics such as amoxicillin; phenoxymethylpenicillin (PcV); clindamycin;
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metronidazole; and the combination of amoxicillin and metronidazole have been widely used
in the implant dentistry field (Table 1).
5.1. Amoxicillin
Amoxicillin is derived from one of the oldest antibiotics, penicillin, which was discovered in
1928 by Alexander Fleming. It is a broad-spectrum antibiotic compound commonly used
during invasive dental procedures as it shows a good and predictable absorption and bioa‐
vailability [106]. It has a bactericidal activity against gram-positive and gram-negative
microorganisms. In addition, it is active against several members of the oral commensal
microflora, such as viridans streptococci, and is thus expected to reduce the risk of local and
systemic infection after dental procedures. The molecular structure of amoxicillin includes a
β-lactam ring that may be cleaved by bacterial enzymes.
The combination of amoxicillin and clavulanic acid, the beta-lactamase inhibitors, is used to
treat infections with β-lactamase producing bacteria. This combination results in an antibiotic
with a broader spectrum of action and restored efficacy against amoxicillin-resistant bacteria,
which produce β-lactamase.
5.2. Penicillin-V
Penicillin-V is a widely used antibiotic in dentistry and possesses several beneficial charac‐
teristics. It achieves peak serum levels within 30 min, and persistent, detectable levels for up
to 4 h after administration [106]. It has a bactericidal action with a narrow microbial spectrum,
and it is highly effective against most Streptococcus species and oral anaerobes [106]. Penicillin-
V is recommended as the drug of choice for the treatment of dental infections in Scandinavian
countries. However, it is seldom used outside Scandinavia mainly because it is not available
for purchase in many countries. The wide use of penicillin-V instead of broad-spectrum
compounds is considered to be an important factor contributing to the low rates of antibiotic
resistance seen in Scandinavian countries.
5.3. Metronidazole
Metronidazole has a unique bactericidal effect against anaerobic bacteria. It is a narrow-
spectrum antibiotic, which minimizes the risk of opportunistic pathogens among commensal
microbiota and reduces the risk of developing a resistant species. There is no known allergic
or hypersensitivity reactions to metronidazole, and it has limited side effects which are
generally tolerable, transient, or reversible [107].
5.4. Clindamycin
Clindamycin is a broad-spectrum compound active against oral anaerobic and aerobic
bacteria, such as streptococci and staphylococci, although its use in dentistry is recommended
mainly in patients with a penicillin allergy [106]. It is bacteriostatic in normal concentrations
and has good bone penetration [91]. Because of its broad-spectrum effect, it gives significant
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and long-term effects on the protective resident microflora and is associated with the devel‐
opment of Clostridium difficile gastroenteritis [108, 109].
5.5. Antibiotic combination therapy
Peri-implant subgingival microbiota contains several putative periodontopathic species with
different antimicrobial susceptibility. Therefore, antibiotic combination may be useful because
of its wider spectrum of activity compared with a single agent. Combination drug therapy may
reduce the possibility of developing bacterial resistance due to antimicrobial spectrum overlap,
or it may be combined in a synergetic way when targeting organisms, allowing the dose of a
single agent to be lowered [110]. However, such combinations may lead to increased adverse
reactions. Recently, the combination of metronidazole and amoxicillin has become a popular
treatment modality for many dentists and researchers.
6. Consequences of antibiotic treatment
No antibacterial drug is completely nontoxic, and its use carries accompanying risks, which
has to balance the benefits and risks of its use before prescribing. The most common side-effects
are gastrointestinal, ranging in severity from frequent self-limiting gastrointestinal upset to
rare life-threatening pseudomembranous colitis. Other relatively common adverse effects are
hypersensitivity reactions ranging from mild to life-threatening anaphylactic reactions [110].
However, the majority of these reactions are mild and limited to a rash or skin lesions in the
head or neck region. Another negative impact of the over prescription of antibiotics is the cost
to the healthcare system. A survey performed in USA suggested that while the cost of antibiotic
prophylaxis is low to the individual, the potential cost to the healthcare system may be well
over $150 million annually [111].
Figure 2. The effect of antibiotic treatment on the ecology of the normal microflora [112–114].
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It is well known that the administration of antimicrobial agents causes a disturbance in the
oropharyngeal and intestinal microflora, which is considered to be important for health
maintenance. This disturbance is not only due to the spectrum of agents, but also to their degree
of absorption, route of elimination, possible enzymatic inactivation and/or binding to human
fluids and intestinal material [112]. Individual variations in normal microflora further
determines the ecological outcome of antimicrobial therapy [112]. Selective pressure by the
administration of antibiotics will decrease the number of microorganisms in the oral cavity.
Consequently, this leads to a disturbance in human microbial ecology as shown in Figure 2
[112–114].
Antibiotic resistance has become a global growing health problem. The golden age of antibiotic
therapy is now coming to an end as stated in 2014 by WHO [115]. However, some researcher
believes that we are already in the pre-antibiotic era. The Global Economic Forum reported
that the development of antibiotic resistance has major societal risks and increases both
morbidity and mortality of affected individuals [115, 116]. Each year there are thousands of
deaths, and millions of dollars spent on healthcare costs due to resistant infections [117].
Therefore, a restrictive approach towards using antibiotics is mandatory in order to limit the
development of microbial antibiotic resistance and avoid the risk of unwanted systemic effects
of antibiotics for the treated individual.
7. Future prospective and knowledge gap
The prescription of antibiotics in medical practice needs to be addressed globally, particularly
in the dental field, including dental implant procedures [29]. In fact, there is a decrease in
surgical infection rate incidence even without the use of antibiotics, yet there is still an increase
in antibiotic prescriptions [118]. There are a lot of factors influencing the prescription of
antibiotics by healthcare practitioners including patients request, gap in knowledge and
practitioner’s education. Indeed, considering the serious situation regarding emerging and
quickly disseminating antibiotic resistance there is no justification for prescription antibiotics
without medical indication [29].
Within the literature, there is a lack of scientific evidence showing the additive effect of
antibiotics, either prophylactic or therapeutic, in the treatment of dental implant. However,
with the demands on restrictive antibiotic policy more studies are needed to assess the benefit
of antibiotic prescription and the safety to refrain from its use. In order to restrict antibiotic
use to fields where it has unquestioned medical value, it is important to investigate the need
for antibiotics. Therefore, additional RCTs with larger sample sizes and longer follow-up
period are needed to determine the role of antibiotic prophylaxis during implant insertion to
prevent early implant failure in both uncomplicated/straight forward and complicated cases.
Furthermore, different type of complicated cases such as immediate insertion into extraction
site, bone augmentation procedures, full jaw surgery and implant surgery in the medically
compromised patient, may pose a variable risk of postoperative infection and should therefore
be studied separately. In the treatment of peri-implantitis, there is a critical need for double-
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blinded placebo-controlled randomized clinical trials to demonstrate the efficacy of adjunctive
use of systemically delivered antibiotics [80]. Furthermore, more studies are needed to evaluate
antibiotic prescriptions from the societal and cost-effective perspectives, not just from the
healthcare perspective.
Figure 3. Tips for the clinician regarding antibiotic prescription in implant dentistry.
Finally, there is a need for recommendations to limit and optimize the utilization of antibiotics
in the dental implant field. This recommendation may result in a more sustainable antibiotic
usage, preventing the risk of infection, which in turn can improve the results of a surgical
intervention, reduce the risk of resistant bacterial strains developing, reduce the total use of
antibiotics, and possibly reduce the cost of care [119]. Based on available evidence some
summarized suggested advices to the clinician are presented in Figure 3.
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